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Abstract
Background: Whereas 40 % to 70 % of papillary thyroid carcinomas (PTCs) are characterized by a BRAF mutation
(BRAFmut), unified biomarkers for the genetically heterogeneous group of BRAF wild type (BRAFwt) PTCs are not
established yet. Using state-of-the-art technology we compared RNA expression profiles between conventional
BRAFwt and BRAFmut PTCs.
Methods: Microarrays covering 36,079 reference sequences were used to generate whole transcript expression
profiles in 11 BRAFwt PTCs including five micro PTCs, 14 BRAFmut PTCs, and 7 normal thyroid specimens. A p-value
with a false discovery rate (FDR) < 0.05 and a fold change > 2 were used as a threshold of significance for
differential expression. Network and pathway utilities were employed to interpret significance of expression data.
BRAF mutational status was established by direct sequencing the hotspot region of exon 15.
Results: We identified 237 annotated genes that were significantly differentially expressed between BRAFwt and
BRAFmut PTCs. Of these, 110 genes were down- and 127 were upregulated in BRAFwt compared to BRAFmut PTCs. A
number of molecules involved in thyroid hormone metabolism including thyroid peroxidase (TPO) were differentially
expressed between both groups. Among cancer-associated molecules were ERBB3 that was downregulated and
ERBB4 that was upregulated in BRAFwt PTCs. Two microRNAs were significantly differentially expressed of which
miR492 bears predicted functions relevant to thyroid-specific molecules. The protein kinase A (PKA) and the G
protein-coupled receptor pathways were identified as significantly related signaling cascades to the gene set of
237 genes. Furthermore, a network of interacting molecules was predicted on basis of the differentially expressed
gene set.
Conclusions: The expression study focusing on affected genes that are differentially expressed between BRAFwt
and BRAFmut conventional PTCs identified a number of molecules which are connected in a network and affect
important canonical pathways. The identified gene set adds to our understanding of the tumor biology of BRAFwt
and BRAFmut PTCs and contains genes/biomarkers of interest.
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Background
Over the last decades the incidence rate of thyroid cancer
increases worldwide [1]. In Saudi Arabia, thyroid carci-
noma (TC) is considered the second most common cancer
in young women [2]. About 80% of all TCs are PTCs. The
majority of PTCs are histologically classified as conven-
tional PTCs. The follicular variant of PTC (FVPTC) repre-
sents the largest subtype and accounts for about 30% of all
PTCs [3]. Minor and rare subtypes include Hurthle cell
variant PTC and insular PTC which bears an aggressive
clinical behavior [4]. Conventional PTCs are characterized
on the molecular level by a moderate to high frequency of
BRAF mutations (40 % - 70 %) that distinguishes them
from FVPTCs (10 % - 20 %) [5].
BRAF is a cytoplasmic receptor serine/threonine kinase
and a key molecule in the mitogen activated protein
kinase (MAPK) pathway. BRAF is mutated in diverse
human malignancies although frequency and clinical pre-
sentation varies considerably between different types of
cancers [6]. Over 90 % of all BRAF mutations are a valine
by glycine substitution at codon 600 (V600E) in exon 15.
Other BRAF mutations affect commonly codons adjunct
to codon 600. Although the impact of BRAF mutations in
PTC is controversially discussed, many studies found an
association of BRAFmut PTCs with unfavorable clinical
features including larger tumor size, advanced tumor
stage, vessel invasion, capsular invasion, tumor extension,
higher risk for lymph node (LN) involvement, distant
metastasis, and poor prognosis [7-10]. Consistent with
this, patients with a BRAFmut PTC are considerably older
than those with a BRAFwt PTC [5,10]. Whereas a BRAF
mutation represents are valuable target for molecular
therapy in advanced solid tumors including PTCs, mole-
cular profiles of BRAFwt PTCs are less known and genetic
screening for valuable target genes is primarily limited to
research studies [11]. The major deregulated key genes in
the BRAFwt group are RET and RAS. RAS consists of the
highly related genes for HRAS, KRAS, and NRAS. Within
the MAPK pathway the RAS molecules transmit signals
to the downstream target BRAF. The most common
RET/PTC fusions are paracentric fusions with the gene
entitled coiled-coil domain containing 6 (CCDC6) con-
tributing to ~80 % and with the nuclear receptor coacti-
vator 4 (NCOA4) contributing to ~10 % of all known
RET/PTC rearrangements. The frequency of RAS muta-
tions and RET/PTC rearrangements differs between the
populations studied and depends in part on the inclu-
sion/exclusion criteria for the different histological PTC
subtypes [12]. RAS mutations and RET rearrangements
are unlikely to act as molecular drivers for onset of
malignancy as they are already present in benign thyroid
neoplasms [13,14]. This distinguishes them from BRAF
mutations which are virtually absent in precursor lesions
of PTCs.
Until now only a few studies compared expression pro-
files between BRAFwt and BRAFmut PTCs using array
technologies [15-18]. The relevance of expressional
screening in PTC according to their BRAF mutational
status is in part related to the different clinical behavior
of both PTC groups with the necessity to identify appro-
priate biomarkers and in part related to the different
tumor biology of both groups which is not thoroughly
understood [7]. In our study we took advantage of cur-
rent state-of-the-art technology to screen and analyze a
case series of BRAFwt and BRAFmut PTCs for detecting
new biomarkers which could become useful to distin-
guish both groups on the molecular level. We did not
include FVPTCs and other smaller histological subtypes
of PTC in our screening to minimize expressional bias
which might be related to a different histology.
Methods
Thyroid samples
We examined 25 specimens from PTCs and seven nor-
mal thyroid samples (TN) from patients who were trea-
ted surgically in the period between November 2008 and
February 2013 at the King Abdulaziz University Hospital,
Jeddah, and the King Faisal Specialist Hospital &
Research Center (KFSH&RC), Jeddah. In two BRAFmut
PTCs, specimens were derived from a recurrence or a
local metastasis and in one BRAFwt PTC from an LN
metastasis. Normal thyroid specimens were derived from
histopathologically unaffected normal thyroid tissue in
the course of lobo- or thyroidetomies of thyroid lesions
(4 goiters, 1 hyperthyroiditis, 1 PTC, and 1 FVPTC). His-
topathological diagnosis and staging of thyroid lesions
was performed by an experienced oncologic pathologist
(JM) according to established criteria [19,20]. Five
BRAFwt PTCs were classified as micro PTCs (≤ 1 cm).
This study was approved by the Research Ethics Commit-
tee of the King Abdulaziz University, Faculty of Medi-
cine, #358-10, and the Institutional Review Board of the
KFSH&RC, #IRB2010-07, and included written informed
consent provided by the participants.
DNA extraction and BRAF mutational screening
Genomic DNA from fresh-frozen samples was extracted
using the QIAmp DNA tissue kit (Qiagen, Hilden,
Germany). DNA concentration was measured with the
Nanodrop ND-1000 spectrophotometer (Thermo Scienti-
fic, Wilmington, DE). Screening of the BRAF mutational
hotspot region of exon 15 was performed as described ear-
lier involving direct sequencing of PCR products spanning
the region [5].
RNA sample and array processing
Total RNA was extracted from freshly preserved thyroid
tissue specimens using the Qiagen RNeasy Mini Kit
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(Qiagen, Hilden, Germany) including an on-column
DNAse treatment according to manufacturer’s recom-
mendations. Quality of the purified RNA was verified on
an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA). RNA integrity number for all evaluated sam-
ples was at least 5.0. RNA concentrations were deter-
mined using a NanoDrop ND-1000 spectrophotometer.
Samples containing each 250 ng of RNA were processed
using the Ambion WT Expression Kit (Life Technolo-
gies, Austin, TX) and the GeneChip WT Terminal
Labeling and Controls Kit (Affymetrix, Santa Clara, CA)
according to the manufacturers` recommendations.
Fragmentation and endlabeling of samples were moni-
tored by electrophoresis on 3 % agarose gels. Affymetrix
GeneChip hybridization, wash and stain kits were uti-
lized in subsequent processing steps. Hybridization mix-
tures containing each 5500 ng of cDNA were hybridized
at 45°C for 17 hrs and 60 rpm to Affymetrix Human
Gene 1.0 ST GeneChip arrays. Subsequent to wash and
staining at the GeneChip Fluidics Station 450, the arrays
were scanned with the GeneChip Scanner 3000 7G.
Probe cell intensity data (CEL files) were generated
using the GeneChip Command Console Software
(AGCC). Human Gene 1.0 ST GeneChip arrays interro-
gate in total with a set of 764,885 probes 36.079 refer-
ence sequences (NCBI build 36).
Gene Expression Analysis
CEL files were imported to Partek Genomics Suite version
6.6 (Partek Inc., MO) and a log-transformed data set of
robust multi-array averaged (RMA), background-adjusted,
and normalized values was generated. Non-annotated
genes and multiple transcripts generated from the same
gene were excluded from further analysis. Principal com-
ponent analysis (PCA) was performed to assess quality as
well as overall variance in gene expression between groups
of samples. Analysis of Variance (ANOVA) was applied to
generate a list of differentially expressed genes using a
p-value with a false discovery rate (FDR) (Step up method)
< 0.05 and a fold change > 2.0. Two dimensional average
linkage hierarchical clustering was performed using Spear-
man’s correlation as a similarity matrix. The generated
array data set complies with MIAME [21] and was sub-
mitted to NCBI’s Gene Expression Omnibus (GEO),
accession number GSE54958.
Functional network and pathway analysis
To define molecular networks and canonical pathways
in differentially regulated gene sets, pathway analyses
were performed by using Ingenuity Pathways Analysis
(IPA) software (Ingenuity Systems, Redwood City, CA).
For this purpose, statistically differentially expressed
genes and their corresponding probe set ID, gene sym-
bol as clone identifier, p-value and fold change were
imported into IPA. The program identifies with its func-
tional algorithms those biological functions, interacting
drugs and/or diseases that are most significantly related
to a differentially expressed gene set. The canonical
pathway analysis identifies pathways that are most sig-
nificantly related to the data set.
Results
Demographic data of patients and histopathological cri-
teria of BRAFwt and BRAFmut PTC are listed in Table 1.
A gender shift towards females was observed in the
BRAFwt group and mean age was considerable lower in
the BRAFwt than in the BRAFmut group (30.9 years vs.
45.9 years). Histopathological criteria including tumor
size, LN involvement, tumor focality and tumor stage
were comparably more unfavorable in BRAFmut PTCs
(Table 1).
Expression BRAFwtvs. BRAFmut PTCs
Employing whole-transcript microarrays (HuGene 1.0
ST) we compared expression profiles of 11 BRAFwt
PTCs with 14 BRAFmut PTCs. Seven TN specimens
were used as a reference for normal thyroid tissue
expression which allowed us to identify differentially
expressed genes between both PTC groups and TN
samples. Three-D presentation of the PCA displays
Table 1 Demographic and clinicopathological features of
BRAFwt and BRAFmut PTCs
Characteristics PTCs
Patient BRAFwt (N = 11) BRAFmut (N = 14)
age (year)
Mean ± SD 30.9 ±12.2 45.9 ±16.4
Ë‚ 45 9 7
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clustering of BRAFwt PTCs, BRAFmut PTCs and TN
samples (Figure 1). We identified, after excluding non-
annotated genes and multiple transcriptional isoforms,
237 annotated genes that were significantly differentially
expressed (p-value with FDR <0.05 and a fold change
>2) between BRAFwt and BRAFmut PTCs (Additional
file 1). Of these genes, 127 were up-, and 110 were
downregulated in BRAFwt compared to BRAFmut PTCs.
The most significantly upregulated genes in BRAFwt
were inositol 1,4,5-triphosphate receptor, type 1 (ITPR1),
hepatic leukemia factor (HLF), potassium voltage-gated
channel, shaker-related subfamily, beta member 1
(KCNAB1), engulfment and cell motility 1 (ELMO1),
Rho GTPase activating protein 24 (ARHGAP24), thyroid
peroxidase (TPO) and solute carrier family 4, sodium
bicarbonate cotransporter, member 4 (SLC4A4). The
most significantly downregulated genes in BRAFwt PTCs
were dendrocyte expressed seven transmembrane protein
(DCSTAMP), ladinin 1 (LAD1), keratin 19 (KRT19),
chromosome 19 open reading frame 33 (C19orf33), polio-
virus receptor-related 4 (PVRL4), EPH receptor A10
(EPHA10), and TBC1 domain family, member 2
(TBC1D2). The list of 237 genes contained one micro-
RNA (MIR492) that was downregulated and one micro-
RNA (MIR32) that was upregulated in BRAFwtvs.
BRAFmut PTCs. Additional file 1 contains also the cellu-
lar/extracellular location, function of gene products as
well as a selection of drugs known to interact with a
gene product. Hierarchical cluster analysis of the 237
genes separates both PTC groups according to their dif-
ferential gene expression (Figure 2). TN samples were
included in this data set to provide normal expression
values.
Expression PTCs vs. TN samples
Comparison of genes differentially expressed between
BRAFwt and TN samples revealed a set of 8249 genes and
between BRAFmut and TN samples a set of 8836 genes. To
identify genes of interests, e.g. conceivable immunohisto-
chemistry markers, we selected those genes which are dif-
ferentially expressed between all three groups (Table 2). In
sum, 32 genes met the statistical criteria and the vast
majority revealed the comparatively highest expression in
BRAFmut PTCs.
Gene networks and canonical pathways
Most significant network functions identified by IPA
algorithms and associated with the set of 237 differen-
tially expressed genes were involved in cell signaling, can-
cer, and cellular development (Figure 3). This
comprehensive network includes 12 molecules which are
overexpressed and 16 molecules which are underex-
pressed in BRAFwt compared to BRAFmut PTCs. The
most significantly associated canonical pathway related
to the differentially expressed set of 237 genes is the pro-
teinkinase A (PKA) signaling cascade (Additional file 2).
The PKA pathway is involved in second messenger sig-
naling and it is stimulated by upstream cascades includ-
ing the G protein-coupled receptor pathway (Figure 4).
The most significant pathways with thyroid specific func-
tions were the thyroid hormone metabolic and thyrona-
mine/iodothyronamine metabolic pathways.
Figure 1 PCA scatter plot wherein each dot represents a sample with a group specific color. Distance between dots is a dimensional measure
for the similarity of the respective expression profiles of the samples. Ellipsoids are a measure to visualize distance of relationships between
samples of a group. Red, normal thyroid; blue, BRAFwt PTCs, green, BRAFmut PTCs.
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Figure 2 Hierarchical cluster analysis of 237 genes which were differentially expressed between BRAFwt and BRAFmut PTCs. Gene expression of
TN samples is included in analysis. Color scheme for expression levels: red for comparably higher and blue for comparably lower expression.
Color scheme for groups in the left sided branches: green for TN samples, purple for BRAFwt, and red for BRAFmut PTCs. Stars mark samples from
recurrence or local metastasis, and LN metastasis.
Table 2 Differentially expressed genes between BRAFwt and BRAFmut PTCs and TN samples






FC1 P FC1 P FC1 P2
keratin 19 KRT19 -4.39 1.3E-09 2.37 2.0E-04 10.43 8.5E-13
potassium voltage-gated channel, shaker-related subfamily, beta member 1 KCNAB1 7.66 6.4E-09 3.23 5.5E-04 -2.37 5.7E-03
solute carrier family 26, member 4 SLC26A4 7.59 4.3E-08 2.14 2.9E-02 -3.55 4.0E-04
TBC1 domain family, member 2 TBC1D2 -2.39 4.4E-08 2.71 1.0E-07 6.48 3.3E-14
tumor protein D52-like 1 TPD52L1 -2.46 3.2E-07 2.22 3.6E-05 5.46 1.1E-11
TP53 apoptosis effector PERP -2.09 3.6E-07 2.97 6.9E-09 6.22 1.6E-14
Periplakin PPL -2.53 1.0E-06 2.92 1.9E-06 7.41 2.3E-12
growth differentiation factor 15 GDF15 -5.08 1.5E-06 2.41 1.1E-02 12.23 6.8E-09
deltex homolog 4 (Drosophila) DTX4 -3.31 3.5E-06 3.28 5.6E-05 10.86 8.4E-11
death-associated protein kinase 2 DAPK2 -2.45 1.0E-05 2.78 2.1E-05 6.83 7.6E-11
ethanolamine kinase 2 ETNK2 -2.51 1.9E-05 2.02 3.0E-03 5.07 1.3E-08
solute carrier family 34 (sodium phosphate), member 2 SLC34A2 -4.75 2.2E-05 8.86 2.2E-06 42.09 1.9E-11
transmembrane protein 98 TMEM98 -2.09 2.8E-05 2.24 9.8E-05 4.69 6.2E-10
gamma-glutamylcyclotransferase GGCT -2.52 3.1E-05 2.48 3.7E-04 6.26 2.3E-09
purine nucleoside phosphorylase PNP -3.55 3.4E-05 2.48 6.6E-03 8.82 4.7E-08
protein S (alpha) PROS1 -2.80 3.7E-05 5.78 1.4E-07 16.18 2.8E-12
FERM domain containing 4B FRMD4B 2.50 3.7E-05 5.04 7.3E-08 2.01 3.1E-03
mucin 1, cell surface associated MUC1 -2.29 5.6E-05 2.23 6.8E-04 5.12 6.6E-09
protein tyrosine phosphatase, receptor type, E PTPRE -2.22 6.0E-05 2.45 1.3E-04 5.43 1.5E-09
gamma-aminobutyric acid (GABA) A receptor, beta 2 GABRB2 -4.73 8.6E-05 2.82 1.7E-02 13.32 3.0E-07
metastasis associated in colon cancer 1 MACC1 -2.34 1.2E-04 2.15 2.3E-03 5.02 4.0E-08
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 CITED1 -3.58 3.4E-04 2.56 1.8E-02 9.17 1.1E-06
laminin, beta 3 LAMB3 -3.13 3.4E-04 2.46 1.2E-02 7.70 6.7E-07
syndecan 4 SDC4 -2.22 4.3E-04 4.25 1.6E-06 9.45 1.2E-10
family with sequence similarity 129, member A FAM129A -2.21 4.3E-04 2.27 1.9E-03 5.03 9.8E-08
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Table 2 Differentially expressed genes between BRAFwt and BRAFmut PTCs and TN samples (Continued)
fibronectin 1 FN1 -2.60 4.9E-04 10.31 8.2E-09 26.78 1.5E-12
phosphodiesterase 5A, cGMP-specific PDE5A -2.82 7.1E-04 6.06 6.7E-06 17.11 6.5E-10
dual specificity phosphatase 5 DUSP5 -2.11 7.9E-04 2.16 3.1E-03 4.57 2.8E-07
chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 -4.45 8.5E-04 3.50 1.4E-02 15.59 1.8E-06
cathepsin H CTSH -2.63 9.2E-04 5.31 1.1E-05 13.97 1.2E-09
trefoil factor 3 (intestinal) TFF3 3.81 1.5E-05 -2.86 2.6E-02 -10.92 5.4E-06
met proto-oncogene (hepatocyte growth factor receptor) MET -2.27 2.7E-11 8.93 1.3E-08 20.25 4.6E-12
1FC, fold change; -, downregulated in BRAFwt PTCs vs. BRAFmut PTCs, downregulated in BRAFwt PTCs vs. TN, and downregulated in BRAFmut PTCs vs. TN; 2p-value
with FDR < 0.05 and fold change cutoff > 2
Figure 3 A molecular network including 12 overexpressed (red) and 16 underexpressed (green) molecules in BRAFwt compared to BRAFmut PTCs.
The relationships between molecules were conveyed by IPA functions on basis of the set 237 differentially expressed genes in BRAFwtvs. BRAFmut
PTCs. Gene names in Additional file 1.
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Discussion
We performed one of the first studies using whole tran-
script microarrays to compare expression profiles solely
in conventional BRAFwt and BRAFmut PTCs. Comparison
to studies including different histological subtypes of
PTCs may result in detecting a lower number of common
genes. An expression array study including histological
variants of PTC identified, on basis of enhanced stringent
threshold criteria, over 80 up- and downregulated genes
in the BRAFmut group in comparison to PTCs with either
a RAS mutation or a RET/PTC rearrangement [15] and
the 40 most up- and downregulated genes have an over-
lap of ~40 % to our list of 237 differentially expressed
genes.
Selected differentially expressed molecules
DCSTAMP, also known as TM7SF4, has been previously
identified as one of the most overexpressed genes in
BRAFmut PTC compared to BRAFwt PTC as well in PTC
with undetermined mutational status compared to normal
thyroid tissue [15,22,23]. It has been supposed that
DCSTAMP expression is an immune response related to
BRAFmut tumors [15]. DCSTAMP contains signature
motifs owned by the family of transmembrane serine pro-
teases and it exhibits degradation activity against extracel-
lular matrix proteins. One of the functions of the hepatic
leukemia factor (HLF) as a transcription factor is to med-
iate thyroid hormone activation from the thyroid hormone
receptor/retinoid X receptor heterodimer to the hypoxia-
inducible factor (HIF-1alpha) [24]. The function of
C19orf33, also known as H2RSP (Hepatocyte growth
factor activator inhibitor type 2-related small protein) is
virtually unknown. An enhanced expression with higher
levels in LN positive tumors has been observed for
C19orf33 in colorectal adenocarcinoma cells at the inva-
sive front [25]. The voltage gated channel molecule
KCNAB1 exhibits diverse functions including electrolyte
transport, and insulin secretion. Downregulation of
KCNAB1 expression has been identified in follicular thyr-
oid carcinomas compared to benign follicular adenomas
[26]. ELMO1 functionally interacts with dedicator of cyto-
kinesis 1 (DOCK1) that promotes Rac guanine exchange
Figure 4 The G protein-coupled receptor pathway is involved in transmembrane signaling and diverse physiological functions including
hormone signaling, regulation of cell contraction, cell migration, growth and differentiation. Members of the G protein-coupled receptors, G
protein alpha q, G protein alpha i/o, and PKA are upregulated (red) whereas members of MAPK phosphatases (MKP), phosphodiesterases (PDE)
and adenylate cyclases (AC) are downregulated (green) in BRAFwt compared to BRAFmut PTCs.
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factor (GEF) activity for Rac proteins of the Rho GTPases
family. GTP-loaded Rac proteins initiate downstream
pathways that promote cell elongation, migration, and
cytoskeleton remodeling [27,28]. The active ELMO1/
DOCK1 complex is anchored via phosphoinositides to the
membrane. In our study, the DOCK1 related DOCK5 gene
was identified as a 2-fold upregulated molecule in BRAFwt
compared to BRAFmut PTCs. The leucine-rich repeat and
immunoglobulin-like domain-containing nogo receptor-
interacting protein 2 (LINGO2) encodes a single-pass type
I membrane protein that is primarily expressed during
development in cells adjunct to the epithelial lining of the
olfactory pit and in adult brain [29]. In our study, LINGO2
was downregulated in BRAFwt PTCs and even more in
BRAFmut PTCs compared to TN samples which may
imply a tumor suppressor function for this molecule.
Higher expression levels of the ERK1/2-specific cytoplas-
mic dual specificity phosphatase 6 (DUSP6) in comparison
to benign and normal thyroid cells has been previously
associated with PTC, especially with advanced thyroid car-
cinomas [30,31]. In our study, DUSP6 was 2.1 times higher
expressed in BRAFmut than in BRAFwt PTCs assuming that
the ERK1/2 related pathway is frequently more utilized in
the BRAFmut group. MET overexpression in thyroid cancer
has been identified in a number of studies and this mole-
cule was 2.3-fold higher expressed in our study in BRAF-
mut compared to BRAFwt PTCs which is in accordance
with another survey [15] (Table 2).
Second messenger molecules
ITPR1 is an intracellular receptor for inositol 1,4,5-trispho-
sphate (IP3) and implicated in the thyroid hormone synth-
esis pathway. The receptor mediates calcium release from
the endoplasmic reticulum upon stimulation by IP3.
Downregulation of ITPR1 has been demonstrated in thyr-
oid cancer in comparison to non-malignant thyroid tissue
in a number of studies [32-35]. Among the members of the
phospholipase C (PLC) family, PLCH1 was upregulated in
BRAFwt PTCs whereas PLCD3 was downregulated. PLC
molecules hydrolyze phosphatidylinositol 4,5-bisphosphate
to generate the second messengers diacylglycerol and IP3.
Thyroid hormone pathway molecules
LAD1 has been identified as an overexpressed gene in
BRAFmut thyroid carcinomas compared to those with a
RET/PTC rearrangement [18]. Lad1 expression is regu-
lated by the glucocorticoid receptor (GR) and requires for
induction the GR coactivators thyroid hormone receptor
associated protein 220 (MED1) and the thyroid hormone
receptor associated protein 170 (MED14) [36]. Downregu-
lation of TPO has been considered in a number of studies
comparing thyroid carcinomas with benign thyroid tumors
or normal thyroid samples [32,33,37,38]. However, down-
regulation of TPO and the sodium iodine symporter genes
as been previously associated with BRAFmut PTCs in
comparison to PTCs with a RET/PTC rearrangement [39].
This is in line with observations that BRAFmut tumors are
refractory for radioactive iodine ablation due to downregu-
lation of thyroid hormone biosynthesis pathways [40].
TPO was in our study 13-fold downregulated in BRAFmut
compared to BRAFwt PTCs. In addition, other genes
involved in thyroid hormone biosynthesis pathway includ-
ing the solute carrier family-5 member-8 (SLC5A8), solute
carrier family 26 (anion exchanger), member 4 (SLC26A4),
deiodinase, iodothyronine, type I (DIO1) and deiodinase,
iodothyronine, type II (DIO2) were downregulated in our
set of BRAFmut PTCs. Other members of the SLC family
that were downregulated in BRAFmut PTCs were SLC1A3,
SLC4A4, SLC16A2, and SLC26A7 whereas SLC22A31,
SLC30A2, and SLC34A2 were downregulated in BRAFwt
PTCs.
ERBB3 and ERRB4 genes
Two of the four structurally related receptor tyrosine
kinases ErbB, namely ERBB3 and ERBB4, were differen-
tially expressed in the two PTC groups, i.e. ERBB3 was
downregulated and ERBB4 upregulated in BRAFwt PTCs
(Additional file 1). Of notice, ERBB4 was also lower
expressed in BRAFmut PTCs compared to TN samples
(p = 0.0035) (data not shown). Oncogenic functions of
ERBB3 and ERBB4, which can form heterodimers and sig-
nal through the PI3K/AKT signaling pathway have not
been elucidated yet in detail in relation to the BRAF muta-
tional status in thyroid cancer [41-43]; however, decreased
expression of ERBB4 in PTC vs. normal thyroid tissue has
been demonstrated in a RT-PCR study whereas ERBB2
and ERBB3 expression was shown to be increased [44].
On the protein level, a tissue microarray study in prolifera-
tive thyroid lesions found a correlation of ERBB3 expres-
sion with LN metastasis whereas ERBB4 expression
correlated with lower tumor stage [45]. A possible link of
ERBB3 to apoptosis can be deduced from a functional in
vivo study wherein deletion of ERBB3 in mouse intestinal
epithelium induced tumor-specific cell death [46].
MicroRNAs
The most significantly downregulated microRNA in
BRAFwt compared to BRAFmut PTCs was mir492 and the
most upregulated one was mir32. Overexpression ofmir492
has been previously linked to progressive hepatoblastoma
and tumorigenesis of retinoblastoma [47,48]. Of notice,
mir492 is processed from the KRT19 gene [47] and both
are higher expressed. A possible target for miR492 is the
3`UTR of KRT19 [49] which is 4.4-fold higher expressed in
BRAFmut PTCs compared to BRAFwt PTCs suggesting an
accumulation of the KRT19 mRNA. Another possible target
of miR492 is the thyroid hormone receptor-associated pro-
tein 3 (THRAP3) mRNA that harbors two predicted target
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sites for miR492 [49] and that is significantly downregulated
in our case series by approximately 3-fold in both, BRAFwt
and BRAFmut PTCs compared to TN samples. Upregulation
of mir32 in thyroid cancer vs. benign thyroid tumors has
been detected in a microarray study; however functional
implication of this microRNA in PTC is not known yet [50].
In summary, our microarray expression study provides a
detailed overview of differentially expressed genes, net-
works, and pathways between BRAFwt and BRAFmut PTCs
that gain interest for basic molecular genetics and transla-
tional studies in PTCs.
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